3.93
-1.26%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ginwa Enterprise Group
Its shares trade on Shanghai under the ticker 600080.SS. It has been listed since 12 June 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥544.0m and net income of CN¥15.6m. At that date it held total assets of CN¥1.93bn and shareholders' equity of CN¥1.56bn.
Ginwa Enterprise (Group) Inc. engages in the manufacture and distribution of pharmaceuticals. The company is headquartered in Xi'An, Shaanxi. The firm's main product is jintiange capsules, used for treatment of osteoporosis. The firm provides products in various forms, including tablets, oral solutions, capsules and others. In addition, the Company involves in the provision of hotel services and operation of rental business. Through its subsidiaries, the Company is involved in hotel operation business, wholesale and retail of pharmaceuticals and medical devices, as well as television drama production businesses and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Jun 1997
- Employees
- 600
- Website
- ginwa.com.cn ↗
Leadership
Pay as last reported
- Mr. Yajiang XingChairman of the Board
- Mr. Chaoyang ZhangVice Chairman of the Board, since 2020
- Mr. Zhuojun HanChief Financial Officer, Deputy General ManagerCN¥336,500
- Ms. Mei ZhangGeneral ManagerCN¥444,000
- Mr. Boyue XingDeputy General Manager, Director
- Ms. Xueyan ChenDeputy General Manager
- Ms. Yanping SongDeputy General Manager
- Yu TaoDeputy General ManagerCN¥274,900
- Mr. Ming SunSecretary of the BoardCN¥250,400
- Ms. Xiaoling LuDirector
- Mr. Chuan QinDirector, since 2006CN¥562,300
- Shengming SunDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ginwa Enterprise Group Inc. manufactures jintiange capsules for osteoporosis treatment.
- The company employs 600 full-time employees in Xi'an, Shaanxi.
- Ginwa offers diverse pharmaceutical products including tablets and oral solutions.
Weaknesses
- Ginwa's business includes hotel services, which may distract from core pharmaceutical focus.
- The company's operations span multiple sectors, potentially diluting expertise.
- Ginwa's subsidiaries handle television drama production, which is unrelated to pharmaceuticals.
Opportunities
- Ginwa can expand its pharmaceutical distribution in China's growing Health Care sector.
- The company's presence in Shaanxi offers access to regional pharmaceutical markets.
- Ginwa's product range includes tablets, oral solutions, and capsules for diverse patient needs.
Threats
- Ginwa's reliance on subsidiaries for hotel operations may create financial instability.
- The company's involvement in television drama production could lead to regulatory scrutiny.
- Ginwa's focus on osteoporosis treatment may limit market diversification opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.